Skip to main content
. 2011 Sep 16;69(2):223–245. doi: 10.1007/s00018-011-0809-0

Fig. 3.

Fig. 3

In the future, therapy choice might be guided by combinations of predictive biomarkers. In the presented example, the presence of one feature and the absence of a second feature might guide treatment with DSB-inducing agents. HR homologous recombination, DSB double-strand break